Development of systemic sclerosis in a patient with systemic lupus erythematosus and topoisomerase I antibody

British Journal of Dermatology

Volumn 142, Issue 5, 2000, Pages 1030-1033

  Katsumi, S ^a   Kobayashi, N ^a   Yamamoto, Y ^a   Miyagawa, S ^a   Shirai, T ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Scl 70 antibody; Systemic lupus erythematosus; Systemic sclerosis; Topoisomerase I antibody

Indexed keywords

DNA TOPOISOMERASE;

ADULT; ARTICLE; CASE REPORT; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; HUMAN; LUNG FIBROSIS; MALE; PRIORITY JOURNAL; SCLERODERMA; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS;

ADULT; ANTIBODIES, ANTINUCLEAR; BIOLOGICAL MARKERS; DNA TOPOISOMERASES, TYPE I; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PREDICTIVE VALUE OF TESTS; SCLERODERMA, SYSTEMIC;

EID: 0034124283     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.2000.03492.x     Document Type: Article

References (17)

1. 1 Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
2. 2 Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-90.
3. 3 Douvas AS, Achten M, Tan EM. Identification of a nuclear protein (Scl-70) as a unique target of human antinuclear antibodies in scleroderma. J Biol Chem 1979; 254: 10514-22.
4. 4 Shero JH, Bordwell B, Rothfield NF et al. High titers of autoantibodies to topoisomerase I (Scl-70) in sera from scleroderma patients. Science 1986; 231: 737-40.
5. 5 Maul GG, van French BT, Venrooij WJ et al. Topoisomerase I identified by scleroderma 70 antisera: enrichment of topoisomerase I at the centromere in mouse mitotic cells before anaphase. Proc Natl Acad Sci USA 1986; 83: 5145-9.
6. 6 Jarzabek-Cholzelska M, Blaszczyk M, Jablonska S et al. Scl-70 antibody - a specific marker of systemic sclerosis. Br J Dermatol 1986; 115: 393-401.
7. 7 Tan EM, Rodnan GP, Garcia I et al. Diversity of antinuclear antibodies in progressive systemic sclerosis. Arthritis Rheum 1980; 23: 617-25.
8. 8 Catoggio LJ, Bernstein RM, Black CM et al. Serological markers in progressive systemic sclerosis: clinical correlations. Ann Rheum Dis 1983; 42: 23-7.
9. 9 van Venrooij WJ, Stapel SO, Houben H et al. Scl-86, a marker antigen for diffuse scleroderma. J Clin Invest 1985; 75: 1053-60.
10. 10 Steen VD, Powell DL, Medsger TA Jr. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 1988; 31: 196-203.
11. 11 Igarashi A, Takehara K, Soma Y et al. Clinical significance of antinuclear antibodies in Japanese patients with systemic sclerosis. Dermatologica 1990; 180: 136-40.
12. 12 Kallenberg CG, Wouda AA, Hoet MH et al. Development of connective tissue disease in patients presenting with Raynaud's phenomenon: a six year followup with emphasis on the predictive value of antinuclear antibodies as detected by immunoblotting. Ann Rheum Dis 1988; 47: 634-41.
13. 13 Thompson D, Juby A, Davis P. The clinical significance of autoantibody profiles in patients with systemic lupus erythematosus. Lupus 1993; 2: 15-19.
14. 14 Mukai M, Sagawa A, Atsumi T et al. 3 cases of anti-Scl-70 (topoisomerase I) antibody associated with central nervous system lupus without renal disorder. J Rheumatol 1993; 20: 1594-7.
15. 15 Stojanov L, Satoh M, Dooley MA et al. Autoantibodies to topoisomerase I in a patient with systemic lupus erythematosus without features of scleroderma. Lupus 1995; 4: 314-17.
16. 16 Ito A, Yasue T. A case of overlap syndrome with SLE and Sjögren's syndrome having anti Scl-70 antibody and later developing PSS. Hifu-Rinsho 1990; 32: 1853-6.
17. 17 Ogata F, Igarashi A, Soma Y et al. Significance of anti Scl-70 antibody in the early diagnosis of systemic sclerosis: report of two cases. Jpn J Dermatol 1993; 103: 931-7.